Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Sociedad Española de Farmacia Hospitalaria
2009
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=365961792004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1 Itziar Oyagüez Miguel A. Casado Manuel Cotarelo Antonio Ramírez-Arellano Josep Mallolas Medicina HIV Efavirenz Tenofovir Emtricitabine Budgetary impact Objective: Estimate the budgetary impact of using a set-dose combination of efavirenzemtricitabine-tenofovir for the Spanish health care system’s treatment of patients infected with HIV-1, while evaluating repercussions for each autonomous community in 2008. Methods: We developed a budgetary impact model with pharmacological costs for the different currently available treatment options, based on GeSida’s recommended guidelines for treating HIV-positive patients. The model deÀnes 5 possible scenarios in which various possibilities for substituting different drug cocktails with the efavirenz-emtricitabine-enofovir combination are contemplated. Results: The investment per patient on a national level amounts to €7989 in the base scenario (without considering the availability of the efavirenz-emtricitabine-tenofovir combination) and to €7997, €8424, €7830, €8375, and €8527 for scenario 1 (substitution of recommended drugs with efavirenz, emtricitabine, and tenofovir or efavirenz, lamivudine, and tenofovir); scenario 2 (substitution of recommended drugs with efavirenz); scenario 3 (substitution of recommended drugs with tenofovir); scenario 4 (substitution of recommended drugs with tenoforvir or zidovudine); and scenario 5 (total substitution), respectively. Compared with the base scenario this means increments of 0.11%, 5.45%, –1.99%, 4.83%, and 6.73% for scenarios 1, 2, 3, 4, and 5. Conclusion: Use of a set combination of efavirenz, emtricitabine and tenofovir to treat adult patients with the HIV-1 virus would lead to slight surpluses or even budgetary savings by decreasing the number of daily doses, which could increase patients’ quality of life and help them stay on the treatment properly. © 2008 SEFH. Published by Elsevier España, S.L. All rights reserved. 2009 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365961792004 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.5 Vol.33